Health Care • Biotechnology: Pharmaceutical Preparations
$17.83 ▼ -0.22
(-1.22%)
MKT CAP: $1.09B • VOL: 905.9K
52W L $12 52W H $35
ROARABLE / RQD
E • 33/100
PIOTROSKI
2 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$15
MEDIAN
$20
MEAN
$20
HIGH
$24
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE JANX TAPE
JANX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $21.57 | $20.50 | 2025-02-14 | $16.23 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $22.47 | $21.04 | 2025-02-06 | $16.76 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $20.33 | $19.61 | 2025-01-29 | $17.12 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $18.19 | — | 2025-01-17 | $17.47 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $15.69 | $16.94 | 2025-01-09 | $15.87 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $21.22 | $18.54 | 2024-12-18 | $15.51 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $17.30 | $18.01 | 2024-12-04 | $16.58 | -4.3% | 48% | C |